A new study reports that maintenance treatment with Olaparib may benefit BRCA1/2 carriers with pancreatic cancer. These findings demonstrated:
long-term survival was more common
time to subsequent therapy was prolonged
Read the full article at the link: https://ascopubs.org/doi/pdf/10.1200/JCO.21.01604
Reference: Kindler et al. J Clin Oncol. 2022; JCO2101604. PMID: 35834777.